FTC: 12- to 14-year exclusivity for biotech drugs too long

06/10/2009 | Reuters

The 12- to 14-year market exclusivity sought by biotech drugmakers to protect their brand name products is too long because there is a good chance these companies will keep "a substantial market share" when generic counterparts gain FDA approval, according to a Federal Trade Commission report. Copycat biotech drugs, or follow-on biologics, are unlikely to be discounted more than 10% to 30% off the price of brand name medicines, according to the report.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC